A decade of dedication
Syncona had identified the Forbes team’s research as a potential candidate for investment, so when their MATCH clinical trial data made a compelling case for the efficacy of macrophage cell therapy on chronic liver disease, the company funded a 2-year research collaboration with Professor Forbes, his team and the SNBTS, with the aim of proving the commercial viability of macrophages as a treatment modality. Access to the University’s world-class facilities at the Centre for Regenerative Medicine, which include a centralised cell culture facility and a state-of-the-art good manufacturing practice (GMP) cellular therapy facility, meant the team were ideally equipped to clear the path to manufacture and file several foundational patent applications. The success of the collaboration motivated Syncona to invest a further £26.6 million to form Resolution Therapeutics and bring the team’s pioneering science to a clinical setting.
From bench to bedside
Edward Hodgkin, Partner at Syncona and now Chairman and CEO of Resolution, is enthusiastic about the company’s trajectory:
“We are excited to partner with the world-class team in Edinburgh as together we build a business that will develop and commercialise macrophage cell therapies to treat severely ill patients who have no other treatment options.
“It is a very exciting opportunity, and we will be at the forefront of the development of a new kind of cell therapy.”